Journal article icon

Journal article

Lack of clinical disease activity response at 4 weeks of baricitinib treatment as a negative predictor of remission at weeks 12 and 24 in patients with rheumatoid arthritis: results from two phase 3 studies (RA-BEAM and RA-BEGIN)

Alternative title:
関節リウマチ患者でのバリシチニブ投与開始12および24週時の 寛解達成に対する負の予測因子としての 投与開始4週時の臨床的疾患活動性における反応性欠如 ―第3相2試験(RA-BEAMおよびRA-BEGIN)の結果―
Abstract:

Objective: To determine whether early changes in disease activity predict later achievement of low disease activity (LDA) or remission in patients treated with baricitinib 4 mg in global phase 3 studies.

Methods: This analysis examined 487 patients and 159 patients randomized to baricitinib 4 mg in RA-BEAM and RA-BEGIN, respectively. Early response was predefined as Clinical Disease Activity Index (CDAI) improvement from baseline to Week 4 of ≥6.0....

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publication website:
https://www.iyaku.info/magazine/?id=1626143232-949722&sf=1&ca3=70

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Sub department:
Botnar Research Centre
Role:
Author
ORCID:
0000-0001-7766-6167
Expand authors...
Publisher:
Iyaku-Joho-Kenkyujo, Inc. Publisher's website
Journal:
新薬と臨牀 [Journal of New Remedies & Clinics] Journal website
Volume:
70
Issue:
7
Pages:
734-751
Publication date:
2021-07-01
Acceptance date:
2021-05-31
ISSN:
0559-8672
Language:
Japanese
Keywords:
Pubs id:
1179884
Local pid:
pubs:1179884
Deposit date:
2021-06-01

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP